Las Vegas Dermatology | Las Vegas, NV

Research site

(Unclaimed)

Location

653 N Town Center Drive, Suite 414, Las Vegas, Nevada, United States of America

Site insights

Top conditions

Top treatments

Dupilumab

Upadacitinib

Cemiplimab

CC-10004

Tirzepatide

Apremilast

DRM01

GIA632

Ixekizumab

Remibrutinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 10 total trials

Locations recently updated

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo (VITESS)

The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632...

Enrolling

Non-segmental Vitiligo

Drug: Placebo

Drug: GIA632

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Enrolling

Atopic Dermatitis

Drug: Upadacitinib 30mg Dose

Drug: Upadacitinib 15mg Dose

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS)

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling

Hidradenitis Suppurativa

Drug: Upadacitinib

Drug: Placebo

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines (RECLAIM)

This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily \[b.i.d.\]...

Enrolling

Chronic Spontaneous Urticaria (CSU)

Drug: Placebo solution for injection

Drug: Dupilumab

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight (TOGETHER-PsO)

The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the pre...

Active, not recruiting

Psoriasis

Obesity

Drug: Tirzepatide

Drug: Ixekizumab

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin...

Enrolling

Cutaneous Squamous Cell Carcinoma (CSCC)

Procedure: Standard of care

Drug: Cemiplimab